MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

詳細記述

書誌詳細

主要な著者:	Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2021-11-01
シリーズ:	JTO Clinical and Research Reports
主題:	Lung cancer MET Nivolumab Amplification Immune checkpoint inhibitor
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2666364321000989
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!